NCT06932848 The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus
| NCT ID | NCT06932848 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chulalongkorn University |
| Condition | Oral Lichen Planus |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind clinical trial evaluates the therapeutic effects of curcumin in nanogels compared to 0.1% fluocinolone acetonide oral paste in the management of atrophic-erosive oral lichen planus (OLP). The study aims to determine whether curcumin nanogels, a natural treatment with enhanced bioavailability, are as effective and better tolerated than standard corticosteroid therapy.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Ability to provide written informed consent * Clinically and histopathologically confirmed diagnosis of erosive or atrophic oral lichen planus (OLP) * Presence of symptoms (NRS pain score \> 0 at baseline) * Ability to communicate and follow instructions * Willingness to apply oral paste treatment and comply with study protocol Exclusion Criteria: * Pregnancy or lactation * Current orthodontic treatment * Uncontrolled diabetes mellitus (HbA1c \> 7% or FPG \> 130 mg/dL) * Use of anticoagulants or antiplatelet agents * Severe dry mouth (Challacombe score \> 7) * History of gastric ulcers, duodenal ulcers, or gallstones * Presence of any active malignancy or infection * Use of topical/systemic treatment for OLP in the past 2 weeks * Current use of immunosuppressants * Known allergy to corticosteroids or herbal agents such as turmeric * Diagnosis of oral lichenoid contact lesion or graft-versus-host disease (GVHD) * History of allogeneic bone marrow transplantation * Current smokers
Contact & Investigator
Pirawish Limlawan, D.D.S., Ph.D.
PRINCIPAL INVESTIGATOR
Faculty of Dentistry, Chulalongkorn University
Frequently Asked Questions
Who can join the NCT06932848 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oral Lichen Planus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06932848 currently recruiting?
Yes, NCT06932848 is actively recruiting participants. Contact the research team at comeblack_ubama@hotmail.com for enrollment information.
Where is the NCT06932848 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT06932848 clinical trial?
NCT06932848 is sponsored by Chulalongkorn University. The principal investigator is Pirawish Limlawan, D.D.S., Ph.D. at Faculty of Dentistry, Chulalongkorn University. The trial plans to enroll 30 participants.